139 related articles for article (PubMed ID: 16195766)
1. Her-2 oncogene amplification, chromosome 17 and DNA ploidy status in synovial sarcoma.
Sápi Z; Pápai Z; Hruska A; Antal I; Bodó M; Orosz Z
Pathol Oncol Res; 2005; 11(3):133-8. PubMed ID: 16195766
[TBL] [Abstract][Full Text] [Related]
2. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.
Ross JS; Sheehan C; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman R; Fisher HA; Muraca PJ
Hum Pathol; 1997 Jul; 28(7):827-33. PubMed ID: 9224752
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma.
Ross JS; Sheehan CE; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman RP; Fisher HA; Rifkin MD; Muraca PJ
Cancer; 1997 Jun; 79(11):2162-70. PubMed ID: 9179063
[TBL] [Abstract][Full Text] [Related]
4. Correlation between DNA ploidy, metaphase high-resolution comparative genomic hybridization results and clinical outcome of synovial sarcoma.
Balogh Z; Szemlaky Z; Szendroi M; Antal I; Pápai Z; Fónyad L; Papp G; Changchien YC; Sápi Z
Diagn Pathol; 2011 Nov; 6():107. PubMed ID: 22053830
[TBL] [Abstract][Full Text] [Related]
5. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.
Thomas DG; Giordano TJ; Sanders D; Biermann S; Sondak VK; Trent JC; Yu D; Pollock RE; Baker L
Cancer; 2005 Feb; 103(4):830-8. PubMed ID: 15641030
[TBL] [Abstract][Full Text] [Related]
6. HER-2/neu oncogene amplification in cervical cancer studied by fluorescent in situ hybridization.
Mark HF; Feldman D; Das S; Sun CL; Samy M; Lathrop J
Genet Test; 1999; 3(2):237-42. PubMed ID: 10464675
[TBL] [Abstract][Full Text] [Related]
7. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Akhdar A; Bronsard M; Lemieux R; Geha S
Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
[TBL] [Abstract][Full Text] [Related]
8. Synovial sarcoma. A Scandinavian Sarcoma Group project.
Skytting B
Acta Orthop Scand Suppl; 2000 Apr; 291():1-28. PubMed ID: 10862210
[TBL] [Abstract][Full Text] [Related]
9. Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma.
Nuciforo PG; Pellegrini C; Fasani R; Maggioni M; Coggi G; Parafioriti A; Bosari S
Hum Pathol; 2003 Jul; 34(7):639-45. PubMed ID: 12874758
[TBL] [Abstract][Full Text] [Related]
10. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.
Tsuda H; Akiyama F; Terasaki H; Hasegawa T; Kurosumi M; Shimadzu M; Yamamori S; Sakamoto G
Cancer; 2001 Dec; 92(12):2965-74. PubMed ID: 11753973
[TBL] [Abstract][Full Text] [Related]
11. Synovial sarcoma. Evaluation of prognosis with emphasis on the study of DNA ploidy and proliferation (PCNA and Ki-67) markers.
Lopes JM; Hannisdal E; Bjerkehagen B; Bruland OS; Danielsen HE; Pettersen EO; Sobrinho-Simões M; Nesland JM
Anal Cell Pathol; 1998; 16(1):45-62. PubMed ID: 9584899
[TBL] [Abstract][Full Text] [Related]
12. Synovial sarcoma. A DNA flow cytometric study.
el-Naggar AK; Ayala AG; Abdul-Karim FW; McLemore D; Ballance WW; Garnsey L; Ro JY; Batsakis JG
Cancer; 1990 May; 65(10):2295-300. PubMed ID: 2161280
[TBL] [Abstract][Full Text] [Related]
13. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
Afify AM; Werness BA; Mark HF
Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
Persons DL; Borelli KA; Hsu PH
Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
[TBL] [Abstract][Full Text] [Related]
15. Mediastinal Synovial Sarcoma: Clinicopathologic Analysis of 21 Cases With Molecular Confirmation.
Terra SBSP; Aesif SW; Maleszewski JJ; Folpe AL; Boland JM
Am J Surg Pathol; 2018 Jun; 42(6):761-766. PubMed ID: 29543673
[TBL] [Abstract][Full Text] [Related]
16. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
[TBL] [Abstract][Full Text] [Related]
17. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
18. [Loss of p53 gene and amplification of HER-2 oncogene in primary hepatocellular carcinoma and their clinical significance].
Huang BJ; Zhu ZY; Liang QW; Fang Y
Zhonghua Bing Li Xue Za Zhi; 2003 Feb; 32(1):20-4. PubMed ID: 12760798
[TBL] [Abstract][Full Text] [Related]
19. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
[TBL] [Abstract][Full Text] [Related]
20. Genetic alterations on chromosome 17 in human breast cancer: relationships to clinical features and DNA ploidy.
Watatani M; Nagayama K; Imanishi Y; Kurooka K; Wada T; Inui H; Hirai K; Ozaki M; Yasutomi M
Breast Cancer Res Treat; 1993 Dec; 28(3):231-9. PubMed ID: 7912561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
